CuraCell doses first patient in TIL therapy trial for colorectal and prostate cancer

Sweden-based CuraCell just dosed the first patient in its phase 1/2a clinical trial evaluating the company’s novel autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer.

The open-label, single-arm study is being conducted at Krankenhaus Nordwest in Frankfurt, Germany. Up to 16 patients with stage IV colorectal and prostate cancer will be enrolled. The primary objective of the study is to assess safety and tolerability, with secondary endpoints including preliminary efficacy, immune profiling, and feasibility of repeated administration.

The study marks the company’s first clinical deployment of its proprietary CytoPLY platform, which enhances activation and enrichment of tumor‑reactive lymphocytes to drive more potent and diverse anti‑tumor responses. CuraCell’s autologous cell therapy involves isolating TILs directly from a patient’s tumor, followed by ex vivo activation and expansion using the CytoPLY platform.